Discover the latest US guidelines recommending oral JAK inhibitors as the primary treatment for severe alopecia areata, offering new hope for hair regrowth.

A quick review of disease prevalence, pathogenesis, subtypes, and treatment approaches.

Study reveals individuals with psychiatric disorders exhibit less flexible brain network dynamics, impacting cognitive state shifts.

New research presented at the International Congress on Obesity found GLP-1 therapy produced statin-like reductions in hsCRP.

Sharon Chung, MD, addresses key questions and challenges in AAV.

Explore the causes of GLP-1 resistance and its impact on diabetes treatment, including potential strategies to overcome it.

Updated algorithms and targets guide more accurate type 2 diabetes diagnosis and long-term treatment goals.

A closer look at metabolic dysfunction-associated steatohepatitis (MASH) risk factors and disease progression. Plus, intervention opportunities identified.

Prevalence, risk factors, and staging for metabolic dysfunction-associated steatohepatitis. Plus, current diagnostic tests and emerging treatments.

A small validation study found that the FUMO Score could accurately predict TED development in individuals diagnosed with Graves’ disease.

Multicenter RCT finds that the IL-1 inhibitor is no better than placebo.

Principal investigator of the ACR/CHEST guideline, Sindhu Johnson, MD, shares clinical strategies for screening and ongoing disease management.

“These new drugs are ones that cardiologists must become more familiar with prescribing,” said Dr. Deepak L. Bhatt.

The heavily endorsed new recommendations add to existing guidance on weight management. Plus, how GLP-1 RAs factor in.

Experts share methods and questions for sustainable weight management with GLP-1 receptor agonists.

The GLP-1 RA may but may still hold disease-modifying promise.

An integrated approach helped improve the tool’s efficacy in a recent study.

Should your practice offer light and laser therapies when traditional acne treatments fall short?

GLP-1 RAs show promise in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis, but findings raise a few questions. An American College of Rheumatology 2025 meeting highlight.

Multidisciplinary GI care access via telehealth showed promise in high-severity patients. An ACG 2025 conference highlight.